| Rebound Play or Scam? Oculus Innovative Sciences' CEO Speaks Up |
 |
 |
| By Staff and Wire Reports | |
| Monday, 26 March 2012 01:16 | |
 Hoji Alimi, founder and CEO of Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) in an exclusive, candid interview with BioMedReports, answers questions about whether his company will ever become a profitable and successfully commercialized biotechnology firm.
Oculus designs, produces and markets safe and effective tissue care products based upon the Microcyn® Technology platform, which significantly reduces the need for antibiotics while reducing infections and accelerating healing. During their development phase, some opinion leaders in the space doubted whether the firm would ever successfully gain FDA approval for their various products, some calling Microcyn® little more than “diluted bleach.” Alimi took exception but he and his team were happy to push the tissue care product pipeline forward. Now they look back armed with seven FDA clearances, several new partnerships and preparations are underway to launch more Microcyn® based products in the dermatology and hospital wound-care markets. Still, the doubters continue to harp on Alimi, who served as a corporate biologist for Arterial Vascular Engineering, where also designed and managed toxicology projects related to that firm’s products from 1995 to 1999. Alimi, who has never been shy about taking on his most vociferous critics attempted to set the record straight at the recent Roth Capital Growth Conference. Speaking to BioMedReports' M.E. Garza he attempts to answer some of the questions investors and the markets want answers to. The full video interview with Hoji Alimi, CEO of Oculus Innovative Sciences is available below: "Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'. Add this page to your favorite Social Bookmarking websites            |
Newsletter
